JACC This Week podcast

Monotherapy in HBR Patients: What STOPDAPT-3 Tells Us | JACC Baran

0:00
31:30
Spol 15 sekunder tilbage
Spol 15 sekunder frem

Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Nobuhiro Ikemura, MD, welcome Yuki Obayashi, MD, of Leiden University Medical Center, to discuss findings from the STOPDAPT-3 trial. Dr. Obayashi highlights that, among ACS patients—including those with HBR or STEMI—aspirin and clopidogrel monotherapy after 1 month of DAPT resulted in similar rates of ischemic and bleeding events. These results support flexible, patient-centered antiplatelet strategies beyond the acute phase.

Flere episoder fra "JACC This Week"